Malignant Peripheral Nerve Sheath TumorSymptoms, Doctors, Treatments, Advances & More
Malignant Peripheral Nerve Sheath Tumor Overview
Learn About Malignant Peripheral Nerve Sheath Tumor
- Malignant peripheral nerve sheath tumor
- MPNST
- Malignant neurilemmoma
- Malignant neurofibroma
- Malignant schwannoma
- Neurofibrosarcoma
- Neurogenic sarcoma
Johns Hopkins Children's Center
Dr. Christine Pratilas is a pediatric medical oncologist at the Sidney Kimmel Comprehensive Cancer Center and Associate Professor of Oncology, Pediatrics & Cellular and Molecular Medicine at the Johns Hopkins University School of Medicine. She joined the Hopkins pediatric sarcoma team in 2014. Dr. Pratilas received her undergraduate degree in Biology from Drew University in New Jersey and her medical degree from UMDNJ - Robert Wood Johnson Medical School (now Rutgers University), where she also completed her internship and residency from 1999 to 2002. From 2002 to 2005 she was a fellow in hematology and oncology in the Memorial Sloan Kettering Cancer Center (MSKCC) Department of Pediatrics, and in the Department of Pediatric Hematology and Oncology at New York Weill Cornell Medical Center. She was a postdoctoral research fellow in Dr. Neal Rosen’s Molecular Oncogenesis Laboratory at MSKCC. From 2006 to 2014 she was attending in Pediatric Oncology at MSKCC, specializing in developmental therapeutics & sarcoma. She has been the director of the pediatric sarcoma program at Hopkins since 2018. Dr. Pratilas focuses her research on cancer-associated pathways and signal transduction, which involves figuring out how a cell’s internal molecular pathways work, and how those pathways can be molecularly controlled. This knowledge is the basis for developing promising new molecularly targeted cancer therapies, which is the focus of Dr. Pratilas’s research. Among her important scientific contributions is advancing our understanding of how certain proteins that can be mutated in cancer, known as RAF kinases (specifically BRAF), affect a cancer cell’s behavior. The research in Dr. Pratilas' laboratory is focused on RAS signal transduction pathways, concentrating on pediatric sarcomas such as rhabdomyosarcoma and malignant peripheral nerve sheath tumors, in order to develop novel therapeutics for children with these tumors. Dr. Pratilas is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 9 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Adult Soft Tissue Sarcoma, and Osteotomy. Dr. Pratilas is board certified in American Board Of Pediatrics.
Cleveland Clinic Main Campus
Gary Schwartz is a Hematologist Oncology provider practicing medicine in Cleveland, Ohio. He has been practicing medicine for over 47 years. Dr. Schwartz is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. He is also highly rated in 32 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Fibrosarcoma, Hepato-Pancreato-Biliary Surgery, and Liver Embolization. Dr. Schwartz is board certified in American Board Of Internal Medicine, 1986.
Washington University
Angela Hirbe is an Oncologist practicing medicine in Saint Louis, Missouri. She has been practicing medicine for over 17 years. Dr. Hirbe is rated as an Elite provider by MediFind in the treatment of Malignant Peripheral Nerve Sheath Tumor. She is also highly rated in 27 other conditions, according to our data. Her clinical expertise encompasses Malignant Peripheral Nerve Sheath Tumor, Fibrosarcoma, Neurofibromatosis Type 1 (NF1), and Adult Soft Tissue Sarcoma.
Summary: The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and ...
Summary: 3CAR is being done to investigate an immunotherapy for patients with solid tumors. It is a Phase I clinical trial evaluating the use of autologous T cells genetically engineered to express B7-H3-CARs for patients ≤ 21 years old, with relapsed/refractory B7-H3+ solid tumors. This study will evaluate the safety and maximum tolerated dose of B7-H3-CAR T cells.The purpose of this study is to find the ...
Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

